The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials?

Détails

ID Serval
serval:BIB_F42A0A6AAD70
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials?
Périodique
International Journal of Cinical Practice
Auteur(s)
Struijker-Boudier H.A., Ambrosioni E., Holzgreve H., Laurent S., Mancia G., Ruilope L.M., Waeber B.
ISSN
1368-5031
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
61
Numéro
9
Pages
1592-1602
Langue
anglais
Résumé
Pharmacological treatment of hypertension represents a cost-effective way for preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment blood pressure (BP) should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (< 130/80 mmHg) if diabetes or renal disease co-exists. Most of the time such targets cannot be reached using monotherapies. This is especially true in patients who exhibit a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases BP control. Such preparations are not only efficacious, but also well tolerated, and some fixed low-dose combinations have a tolerability profile similar to placebo. This is for instance the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has recently been shown in controlled interventional trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving macrovascular stiffness. Fixed-dose combinations are becoming more and more popular and are even proposed by current hypertension guidelines as a first-line option to treat hypertensive patients.
Mots-clé
Antihypertensive Agents, Blood Pressure, Clinical Trials as Topic, Dose-Response Relationship, Drug, Drug Combinations, Humans, Hypertension, Indapamide, Perindopril
Pubmed
Web of science
Création de la notice
06/03/2009 13:01
Dernière modification de la notice
03/03/2018 22:43
Données d'usage